Myosana Therapeutics

About the offering

Myosana Therapeutics is developing a non-viral gene therapy platform for Duchenne muscular dystrophy (DMD) and other muscle and heart diseases. Based in Seattle, the company claims to be the first and only to successfully deliver natural, full-length dystrophin protein to muscles and the heart of animals via intravenous delivery using a single non-viral gene therapy—a breakthrough that addresses the fundamental limitation of existing treatments, which can only deliver a truncated, partial version of the protein. Founded by Dr. Nicholas Whitehead (20+ years in muscle physiology and DMD research, Associate Professor at University of Washington) and Dr. Stan Froehner (40+ years of DMD research, Fellow of AAAS, former department chair at UNC-Chapel Hill and UW), the company has received programmatic investments from three of the most prominent DMD patient advocacy organizations: Parent Project Muscular Dystrophy (PPMD), CureDuchenne, and the Muscular Dystrophy Association (MDA). The Wefunder campaign has raised $252,846 from 12 investors, with a $50,000 featured investment from John Ballantyne (co-founder of Aldevron, which was acquired for $9.6B by Danaher). Early bird terms have $47,154 remaining.The ProblemDuchenne muscular dystrophy is a devastating genetic disease affecting approximately 300,000 boys worldwide. Caused by mutations in the dystrophin gene, the disease progressively destroys muscle tissue: boys typically lose the ability to walk by age 12, and most don't survive past their 20s-30s as heart and respiratory muscles fail. The only currently available gene therapy costs $3.2 million per patient and delivers only a truncated, partial version of the dystrophin protein—essentially a miniaturized fragment of the full protein that the body needs. This is because existing treatments rely on adeno-associated virus (AAV) vectors, which have a strict size limitation that physically cannot accommodate the full dystrophin gene (one of the largest known human genes). The result is a treatment that is prohibitively expensive, delivers an incomplete protein, produces limited clinical improvement, carries severe side effects from immune reactions to the viral vector, and cannot be re-dosed because the patient's immune system develops antibodies against the virus. Scientific literature supports that even tiny amounts of the full-length protein can dramatically improve patient outcomes—the field's inability to deliver the complete protein has been the fundamental bottleneck.The SolutionMyosana has developed a non-viral gene delivery platform that overcomes the size limitations of viral vectors, enabling delivery of the complete, full-length dystrophin gene. The platform uses a targeted delivery mechanism exploiting GLUT4 receptors—protein "doors" that are specific to muscle cells—to direct the therapy precisely to muscle tissue (including cardiac muscle) while avoiding other organs. This muscle-specific targeting allows lower doses and reduces off-target effects.Key advantages over existing viral approaches include the ability to deliver the full-length dystrophin protein (not a truncated version), delivery to both skeletal muscle and heart muscle (critical since cardiac failure is a leading cause of death in DMD), delivery to muscle satellite (stem) cells (enabling long-term muscle repair rather than just treating existing cells), immune neutrality (no viral components to trigger immune reactions), the ability to re-dose (patients can receive treatment multiple times, unlike viral approaches where antibodies prevent re-administration), and potentially accessible pricing compared to the current $3.2M per treatment.In animal studies, the platform restored dystrophin in DMD mice, reduced muscle damage by 85%, and improved muscle strength. The team is now close to selecting the final version for human trials.Beyond DMD, the platform has potential applications in limb-girdle muscular dystrophies, X-linked myotubular myopathy, various heart muscle diseases, and other genetic muscle conditions.Business ModelMyosana is a preclinical-stage biopharmaceutical company developing gene therapies for regulatory approval and commercialization. Revenue would come from approved therapeutic products sold to hospitals and treatment centers. The DMD gene therapy market is estimated at $4B+ for an effective treatment. The current gene therapy (Sarepta's Elevidys) is priced at $3.2M per patient, establishing a high pricing benchmark. Myosana's non-viral approach is positioned to offer more accessible pricing while potentially delivering superior clinical outcomes. The platform's applicability to multiple muscle and heart diseases creates pipeline expansion opportunities.The development plan spans three phases: Phase 1 (next 2 years) focuses on early clinical trials for safety and protein measurement; Phase 2 (years 3-4) expands to larger comparative studies; Phase 3 (years 5-6) completes final approval studies and global launch.TractionThree major DMD patient advocacy organizations—PPMD, CureDuchenne, and MDA—have made programmatic investments in Myosana. These organizations evaluate dozens of potential treatments and their collective endorsement represents the most rigorous form of patient community validation available in the rare disease space. PPMD's VP of Research and Clinical Innovation specifically cited "compelling preliminary evidence" that the platform can deliver full-length dystrophin to muscle tissue.Featured investor John Ballantyne co-founded Aldevron in 1998 and served as Chief Scientific Officer through 2021; Aldevron was acquired by Danaher for approximately $9.6B, making Ballantyne's $50,000 investment a credible signal from someone with deep gene therapy manufacturing expertise. He is also a founder of Agathos Biologics and a partner in the Kineticos Disruptor Fund.The Wefunder campaign has raised $252,846 from 12 investors (averaging over $21,000 per investor—an unusually high average indicating sophisticated investor participation). The team has combined experience of over 200 years in treating muscular dystrophy. Animal study data shows dystrophin restoration, 85% reduction in muscle damage, and improved muscle strength in DMD mice. Evidence of delivery to muscle satellite (stem) cells has been generated. The company is close to selecting the final candidate version for human trials. No specific valuation, deal terms, or total prior funding were disclosed in the available materials.Market OpportunityApproximately 300,000 boys worldwide are affected by DMD, with the market for effective therapy estimated at $4B+. The current treatment benchmark is $3.2M per patient (Sarepta's Elevidys), establishing significant pricing power for a demonstrably superior therapy. The market is growing as diagnostic awareness increases and more patients are identified. Beyond DMD, the platform addresses limb-girdle muscular dystrophies, X-linked myotubular myopathy, cardiac muscle diseases, and other genetic muscle conditions—each representing additional multi-billion-dollar market opportunities. Gene therapy and rare disease treatments have historically achieved billions in sales, with first-to-market therapies often dominating their fields.TeamCEO, Co-Founder, and CSO Dr. Nicholas Whitehead has over 20 years of expertise in muscle physiology and DMD research, holds a PhD from Monash University (Australia), serves as Associate Professor at the University of Washington, has published pivotal research on novel roles of dystrophin, and is the inventor of Myosana's technology. Co-Founder and Chairman Dr. Stanley Froehner has conducted research on DMD for more than 40 years, was educated at UT Austin, Caltech, and Harvard, served as department chair at UNC-Chapel Hill and University of Washington, and is an elected Fellow of the American Association for the Advancement of Science. He pioneered the concept of the dystrophin complex as a scaffold for signaling proteins—foundational science for understanding DMD. Advisor and early investor Dr. Matt Lumley is a physician scientist with nearly 20 years of experience in academic medicine and drug development, earned his medical degree from Imperial College and PhD from Kings College, and previously worked at Pfizer, Moderna, and Medicxi (a leading life sciences VC). His son Myles has DMD, providing deeply personal motivation. The team's combined 200+ years of DMD experience is not a marketing claim but a reflection of the scientific depth required to make progress on this disease.

FAQ